Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
March 3, 2021

Coronavirus company news summary – Aegea and Biocept announce supply agreement for new Covid-19 test – Co-Diagnostics to develop new Covid-19 diagnostic testing platform

By Chloe Kent

Aegea Biotechnologies, a life science company, and Biocept, a molecular diagnostic assays provider, have announced a supply agreement for a new PCR-based Covid-19 assay test kit co-developed by the companies. Aegea will supply the COVID-19 assay kit to Biocept for validation in its CLIA-certified, CAP-accredited high-complexity molecular lab and subsequent commercialization of a laboratory developed test (LDT).

Enzo Biochem has announced that its proprietary GENFLEX molecular diagnostic platform successfully detects the presence of Covid-19 variants. While its PCR testing does not differentiate between different variants, positive samples can be analysed further for variants. Current rapid antigen tests in the marketplace do not have this ability.

Co-Diagnostics is developing a new point-of-care, at-home PCR diagnostic testing, screening, and surveillance platform, capable of detecting Covid-19 and other diseases using its CoPrimer technology. The test can be performed at businesses, homes, schools, hotels, airports, airplanes, cruise ships, and in other locations.

Related Companies

Content from our partners
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy